CORBUS PHARMACEUTICALS HLDGS ($CRBP) posted quarterly earnings results for Q3 2026 on Tuesday, November 10th. The company reported earnings of -$1.81 per share, missing estimates of -$1.24 by $0.57. The company also reported revenue of $0, missing estimates of $1,275,000 by $-1,275,000.
You can see Quiver Quantitative's $CRBP stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CORBUS PHARMACEUTICALS HLDGS Insider Trading Activity
CORBUS PHARMACEUTICALS HLDGS insiders have traded $CRBP stock on the open market 6 times in the past 6 months. Of those trades, 2 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $CRBP stock by insiders over the last 6 months:
- ASSET MANAGEMENT, LP CORMORANT sold 425,000 shares for an estimated $1,742,755
- YUVAL COHEN (Chief Executive Officer) sold 17,000 shares for an estimated $171,395
- SEAN F. MORAN (Chief Financial Officer) sold 12,000 shares for an estimated $120,970
- NISHANT C SAXENA (Chief Business Officer) has made 2 purchases buying 13,500 shares for an estimated $101,218 and 0 sales.
- YONG BEN sold 2,000 shares for an estimated $15,683
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
CORBUS PHARMACEUTICALS HLDGS Hedge Fund Activity
We have seen 59 institutional investors add shares of CORBUS PHARMACEUTICALS HLDGS stock to their portfolio, and 57 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ABERDEEN GROUP PLC removed 1,321,750 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $9,014,335
- BLACKROCK, INC. added 1,059,499 shares (+390.0%) to their portfolio in Q2 2026, for an estimated $9,938,100
- JONES HILL CAPITAL LP added 653,572 shares (+inf%) to their portfolio in Q2 2026, for an estimated $6,130,505
- ARMISTICE CAPITAL, LLC removed 364,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $3,414,320
- DIADEMA PARTNERS LP added 301,264 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,825,856
- RENAISSANCE TECHNOLOGIES LLC removed 236,176 shares (-68.1%) from their portfolio in Q2 2026, for an estimated $2,215,330
- DAFNA CAPITAL MANAGEMENT LLC added 107,773 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,010,910
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
CORBUS PHARMACEUTICALS HLDGS Price Targets
Multiple analysts have issued price targets for $CRBP recently. We have seen 4 analysts offer price targets for $CRBP in the last 6 months, with a median target of $37.0.
Here are some recent targets:
- Graig Suvannavejh from Mizuho set a target price of $34.0 on 06/23/2026
- Jeff Jones from Oppenheimer set a target price of $52.0 on 06/17/2026
- Robert Driscoll from Wedbush set a target price of $30.0 on 05/27/2026
- Andres Y. Maldonado from HC Wainwright & Co. set a target price of $40.0 on 05/26/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
